USFDAJul 15, 2026, 09:02 AM
NeOnc Receives FDA Feedback on NEO212 CMC Development
AI Summary
NeOnc Technologies Holdings, Inc. announced it received detailed written feedback from the U.S. Food and Drug Administration (FDA) regarding the chemistry, manufacturing and controls (CMC) development program for its drug candidate, NEO212. This feedback was sufficiently clear, allowing the company to cancel its scheduled Type B End-of-Phase 1 meeting. The FDA's comments provide greater clarity on manufacturing, formulation, and bioavailability requirements, particularly for the transition from a capsule to a tablet formulation, which NeOnc is now integrating into its development plan.
Key Highlights
- FDA provided written feedback on the CMC development program for NEO212.
- The feedback allowed NeOnc to cancel its Type B End-of-Phase 1 meeting.
- FDA deemed NeOnc's proposed CMC development approach for NEO212 reasonable.
- Drug-product development can proceed in parallel with late-stage clinical program.
- Transition from capsule to tablet formulation requires an in vivo relative bioavailability study.
- FDA identified specific CMC work needed before using tablet material in clinical phases.
- NeOnc is incorporating FDA feedback into its NEO212 development plan.
Price Impact
More from NTHI